Abstract
The beta-blocking agent bufuralol is subject to first-pass metabolism and is eliminated from the body almost entirely by biotransformation. Its major metabolite in plasma (1′-hydroxy-bufuralol) is biologically active and may contribute to the pharmacological effect of the drug. The effect of renal failure on the behavior of the parent compound and three of its metabolites was studied by comparing their kinetics in normal volunteers and in patients with severe renal insufficiency. Bufuralol was given orally to all subjects (20 mg); some of the healthy volunteers also received the drug intravenously (5 mg). Renal failure was found to be associated with a marked increase of the areas under the plasma concentration-time curves of the parent compound, whereas its halflife of elimination was not markedly influenced. The behavior of 1′-hydroxy-bufuralol was consistent with a decreased renal clearance. The behavior of bufuralol in patients with renal failure was analyzed using the clearance approach. From this analysis it appears that the presystemic biotransformation of bufuralol is decreased in renal failure and that changes in systemic clearance are compensated in our patients by modifications of the volume of distribution, resulting in little net change in the halflife of elimination.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
G. Johnsson and C. G. Regårdh. Clinical pharmacokinetics ofβ-adrenoceptor blocking drugs.Clin. Pharmacokin. 1:233–263 (1976).
F. D. Thompson, A. M. Joekes, and D. M. Foulkes. Pharmacodynamics of propranolol in renal failure.Br. Med. J. 2:434–436 (1972).
D. T. Lowenthal, W. A. Briggs, T. P. Gibson, H. Nelson, and W. J. Cirksena. Pharmacokinetics of oral propranolol in chronic renal disease.Clin. Pharmacol. Ther. 16:761–769 (1974).
G. Bianchetti, G. Graziani, D. Brancaccio, A. Morganti, G. Leonetti, M. Manfrin, R. Sega, R. Gomeni, C. Ponticelli, and P. L. Morselli. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.Clin. Pharmacokin. 1:373–384 (1976).
J. M. Tschopp, A. Gorgia, L. Balant, C. Revillard, R. J. Francis, and J. Fabre. Rôle des métabolites dans les relations entre la pharmacocinétique et l'effet des agentsβ-bloquants. Expériences avec le tolamolol et le bufuralol.Schweiz. Med. Wschr. 108:756–764 (1978).
R. J. Francis, P. B. East, S. J. McLaren, and J. Larman. Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.Biodem. Mass. Spectrometry 3:281–285 (1976).
R. J. Francis, J. G. Allen, P. B. East, and R. J. Ruane. The metabolism of bufuralol: urinary metabolite profiles in rat, dog and man.Eur. J. Drug Metab. Pharmacokin. 2:113–124 (1976).
L. Balant, R. J. Francis, J.-M. Tschopp, D. Tinguely, J. Estreicher, and J. Fabre. Pharmacocinétique du bufuralol chez l'homme.Pharm. Acta Helv. 53:307–313 (1978).
K. S. Pang and M. Rowland. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 5:625–653 (1978).
M. Rowland. Influence of route of administration on availability.J. Pharm. Sci. 61:70–74 (1972).
M. Rowland. Effect of some physiologic factors on bioavailability of oral dosage forms. In J. Swarbrick (ed.),Current Concepts in the Pharmaceutical Sciences: Dosage Form Design and Bioavailability, Lea & Febiger, Philadelphia, 1973, pp. 181–222.
L. Balant, A. Gorgia, J.-M. Tschopp, C. Revillard, and J. Fabre. Pharmacocinétique de deux médicaments bêta-bloquants: détection d'une anomalie pharmacogénétique?Schweiz. Med. Wschr. 106:1403–1407 (1976).
K. M. Piafsky, O. Borgå, I. Odar-Cederlöf, C. Johansson, and F. Sjöqvist. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevation of plasmaα 1 acid glycoprotein.N. Eng. J. Med. 299:1435–1438 (1978).
J. H. Bauer and Ch. S. Brooks. The long-term effect of propranolol therapy on renal function.Am. J. Med. 66:405–410 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Balant, L., Francis, R.J., Tozer, T.N. et al. Influence of renal failure on the hepatic clearance of bufuralol in man. Journal of Pharmacokinetics and Biopharmaceutics 8, 421–438 (1980). https://doi.org/10.1007/BF01059544
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059544